10-Q quarterly report · filed Nov 9, 2026

Definium Therapeutics, Inc. (DFTX) Q3 2026 10-Q Quarterly Report

Short answer

Definium Therapeutics, Inc. (DFTX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$51M
+24.2% YoY · +67.9% QoQ
EPS (diluted)
−$0.27
+64.0% YoY · +81.3% QoQ

Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) Q3 2026 10-Q on SEC EDGAR. USD.

Definium Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product candidates commercialized
  • Operating margin not applicable, operating loss $72.3M vs $45.7M YoY
  • Best-performing program: DT120 GAD, external costs $14.7M vs $16.2M YoY
  • Cash, equivalents and investments approximately $1.0B; operating cash use $148.4M for nine months
  • Cash runway into 2030; R&D expenses expected to increase throughout 2026

Risk Factors

  • No material changes to risk factors during the three months ended September 30, 2026
  • Existing 2025 Form 10-K risks remain applicable to business condition, results of operations and cash flows

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Definium Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.